A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
- Author
- BRANA, I1 ; BERGER, R2 ; JONES, M. B9 ; ALMHANNA, K10 ; WENHAM, R. M10 ; SULLIVAN, D. M10 11 ; DALTON, W. S11 ; GUNCHENKO, A9 ; CHENG, J. D9 ; SIU, L. L1 ; GRAY, J. E10 ; GOLAN, T2 ; HALUSKA, P3 ; EDENFIELD, J4 ; FIORICA, J5 ; STEPHENSON, J4 ; MARTIN, L. P6 ; WESTIN, S7 ; HANJANI, P8
[1] Princess Margaret Cancer Centre, Toronto, Ontario, Canada
[2] Sheba Medical Center, Ramat Gan, Israel
[3] Mayo Clinic, Rochester, MN, United States
[4] Greenville Health System - Cancer Institute, Greenville, SC, United States
[5] Sarasota Memorial Hospital, Sarasota, FL, United States
[6] Fox Chase Cancer Center, Philadelphia, PA, United States
[7] University of Texas - MD Anderson Cancer Center, Houston, TX, United States
[8] Abington Memorial Hospital, Abington, PA, United States
[9] Merck & Co., Inc., North Wales, PA, United States
[10] H Lee Moffitt Cancer Center, Tampa, FL, United States
[11] M2Gen Tampa, Tampa, FL, United States - Source
British journal of cancer. 2014, Vol 111, Num 10, pp 1932-1944, 13 p ; ref : 1 p.3/4
- CODEN
- BJCAAI
- ISSN
- 0007-0920
- Scientific domain
- Medical oncology
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- MK-0752 MK-2206 colorectal cancer dalotuzumab ovarian cancer ridaforolimus
- Keyword (fr)
- Akt protein kinase Anticancéreux Association médicamenteuse Bras Cancer colorectal Cancer de l'ovaire Cancérologie Essai clinique phase I Homme Stade avancé Tumeur solide Dalotuzumab Inhibiteur mTOR Récepteur IGF de type 1 Récepteur Notch Anticorps monoclonal Cancer Pathologie de l'appareil digestif Pathologie de l'appareil génital femelle Pathologie de l'intestin Pathologie des ovaires Pathologie du côlon Pathologie du rectum Tumeur maligne
- Keyword (en)
- Akt protein kinase Antineoplastic agent Drug combination Arm Colorectal cancer Ovary cancer Cancerology Phase I trial Human Advanced stage Solid tumor Dalotuzumab Type 1 insulin-like growth factor receptor Notch receptor Monoclonal antibody Cancer Digestive diseases Female genital diseases Intestinal disease Ovarian diseases Colonic disease Rectal disease Malignant tumor
- Keyword (es)
- Akt protein kinase Anticanceroso Asociación medicamentosa Brazo Cancer de colon y recto Cáncer del ovario Cancerología Ensayo clínico fase I Hombre Estadio avanzado Tumor sólido Dalotuzumab Receptor Notch Anticuerpo monoclonal Cáncer Aparato digestivo patología Aparato genital hembra patología Intestino patología Ovario patología Colón patología Recto patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20C Female genital diseases / 002B20C02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 29004216
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/bjc.2014.497 
https://dx.doi.org/10.1038/bjc.2014.497
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2014.497\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:231:\"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"111\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1932\";s:8:\"\u0000*\u0000epage\";s:4:\"1944\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BRANA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:9:\"BERGER, R\";i:1;s:11:\"JONES, M. B\";i:2;s:11:\"ALMHANNA, K\";i:3;s:12:\"WENHAM, R. M\";i:4;s:14:\"SULLIVAN, D. M\";i:5;s:12:\"DALTON, W. S\";i:6;s:12:\"GUNCHENKO, A\";i:7;s:11:\"CHENG, J. D\";i:8;s:9:\"SIU, L. L\";i:9;s:10:\"GRAY, J. E\";i:10;s:8:\"GOLAN, T\";i:11;s:10:\"HALUSKA, P\";i:12;s:12:\"EDENFIELD, J\";i:13;s:10:\"FIORICA, J\";i:14;s:13:\"STEPHENSON, J\";i:15;s:12:\"MARTIN, L. P\";i:16;s:9:\"WESTIN, S\";i:17;s:10:\"HANJANI, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:231:\"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2014.497\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:231:\"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"111\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1932\";s:8:\"\u0000*\u0000epage\";s:4:\"1944\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BRANA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:9:\"BERGER, R\";i:1;s:11:\"JONES, M. B\";i:2;s:11:\"ALMHANNA, K\";i:3;s:12:\"WENHAM, R. M\";i:4;s:14:\"SULLIVAN, D. M\";i:5;s:12:\"DALTON, W. S\";i:6;s:12:\"GUNCHENKO, A\";i:7;s:11:\"CHENG, J. D\";i:8;s:9:\"SIU, L. L\";i:9;s:10:\"GRAY, J. E\";i:10;s:8:\"GOLAN, T\";i:11;s:10:\"HALUSKA, P\";i:12;s:12:\"EDENFIELD, J\";i:13;s:10:\"FIORICA, J\";i:14;s:13:\"STEPHENSON, J\";i:15;s:12:\"MARTIN, L. P\";i:16;s:9:\"WESTIN, S\";i:17;s:10:\"HANJANI, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:231:\"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2014.497\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2014.497\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:231:\"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"111\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1932\";s:8:\"\u0000*\u0000epage\";s:4:\"1944\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BRANA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:9:\"BERGER, R\";i:1;s:11:\"JONES, M. B\";i:2;s:11:\"ALMHANNA, K\";i:3;s:12:\"WENHAM, R. M\";i:4;s:14:\"SULLIVAN, D. M\";i:5;s:12:\"DALTON, W. S\";i:6;s:12:\"GUNCHENKO, A\";i:7;s:11:\"CHENG, J. D\";i:8;s:9:\"SIU, L. L\";i:9;s:10:\"GRAY, J. E\";i:10;s:8:\"GOLAN, T\";i:11;s:10:\"HALUSKA, P\";i:12;s:12:\"EDENFIELD, J\";i:13;s:10:\"FIORICA, J\";i:14;s:13:\"STEPHENSON, J\";i:15;s:12:\"MARTIN, L. P\";i:16;s:9:\"WESTIN, S\";i:17;s:10:\"HANJANI, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:231:\"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2014.497\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:231:\"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"111\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1932\";s:8:\"\u0000*\u0000epage\";s:4:\"1944\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BRANA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:9:\"BERGER, R\";i:1;s:11:\"JONES, M. B\";i:2;s:11:\"ALMHANNA, K\";i:3;s:12:\"WENHAM, R. M\";i:4;s:14:\"SULLIVAN, D. M\";i:5;s:12:\"DALTON, W. S\";i:6;s:12:\"GUNCHENKO, A\";i:7;s:11:\"CHENG, J. D\";i:8;s:9:\"SIU, L. L\";i:9;s:10:\"GRAY, J. E\";i:10;s:8:\"GOLAN, T\";i:11;s:10:\"HALUSKA, P\";i:12;s:12:\"EDENFIELD, J\";i:13;s:10:\"FIORICA, J\";i:14;s:13:\"STEPHENSON, J\";i:15;s:12:\"MARTIN, L. P\";i:16;s:9:\"WESTIN, S\";i:17;s:10:\"HANJANI, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:231:\"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2014.497\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:231:\"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"111\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1932\";s:8:\"\u0000*\u0000epage\";s:4:\"1944\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BRANA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"I\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:9:\"BERGER, R\";i:1;s:11:\"JONES, M. B\";i:2;s:11:\"ALMHANNA, K\";i:3;s:12:\"WENHAM, R. M\";i:4;s:14:\"SULLIVAN, D. M\";i:5;s:12:\"DALTON, W. S\";i:6;s:12:\"GUNCHENKO, A\";i:7;s:11:\"CHENG, J. D\";i:8;s:9:\"SIU, L. L\";i:9;s:10:\"GRAY, J. E\";i:10;s:8:\"GOLAN, T\";i:11;s:10:\"HALUSKA, P\";i:12;s:12:\"EDENFIELD, J\";i:13;s:10:\"FIORICA, J\";i:14;s:13:\"STEPHENSON, J\";i:15;s:12:\"MARTIN, L. P\";i:16;s:9:\"WESTIN, S\";i:17;s:10:\"HANJANI, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:231:\"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
